Compare CHRD & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CHRD | SYRE |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 8.7B |
| IPO Year | 2010 | 2015 |
| Metric | CHRD | SYRE |
|---|---|---|
| Price | $145.79 | $94.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 18 |
| Target Price | ★ $182.75 | $123.87 |
| AVG Volume (30 Days) | 769.9K | ★ 876.8K |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | ★ 3.54% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 14.47 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $53.11 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $87.35 | $23.01 |
| 52 Week High | $159.96 | $110.64 |
| Indicator | CHRD | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 50.91 | 47.08 |
| Support Level | $130.54 | $93.28 |
| Resistance Level | $152.12 | $104.15 |
| Average True Range (ATR) | 5.62 | 5.16 |
| MACD | 0.19 | -0.52 |
| Stochastic Oscillator | 56.81 | 10.58 |
Chord Energy Corp is an independent exploration and production (E&P) company engaged in the acquisition, exploration, development and production of crude oil, NGL and natural gas prominently in the Williston Basin, with limited non-operated interests in the Marcellus Shale. It operates in one reportable business segment, which is the E&P of crude oil, NGL and natural gas. The company derives revenue from the sale of crude oil, NGL and natural gas production.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.